Price (delayed)
$2.8
Market cap
$23.69M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.91
Enterprise value
-$4.08M
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases, has a current portfolio of 4 drug candidates. The
There are no recent dividends present for NRBO.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.